UBRELVY 50 mg/1

UBRELVY 50 mg tablets contain ubrogepant, a medication used for the acute treatment of migraines. This oral medication is designed to provide relief from migraine pain and associated symptoms. Ubrogepant is a selective calcitonin gene-related peptide (CGRP) receptor antagonist.

UBRELVY 50 mg tablets are primarily used for the acute treatment of migraines with or without aura in adults. This medication is intended to alleviate the pain and other symptoms associated with migraines. Ubrogepant works by blocking the activity of CGRP, a protein involved in migraine attacks. It is important to consult a healthcare provider to determine if this medication is suitable for your specific condition.

Common effects of Ubrevly 50 mg tablets may include nausea, somnolence, and dry mouth. Some users may experience fatigue or dizziness. These effects are generally mild and temporary. If you experience severe or persistent side effects, it is advisable to seek medical attention.

UBRELVY 50 mg tablets should be used with caution in individuals with a history of liver problems or those taking certain medications that affect liver enzymes. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Pregnant or breastfeeding women should consult their healthcare provider before using this medication.

UBRELVY 50 mg tablets may interact with other medications, including those metabolized by the liver enzyme CYP3A4. It is important to avoid alcohol while taking this medication, as it may increase the risk of side effects. Always inform your healthcare provider about all medications, supplements, and herbal products you are taking to ensure safe and effective use.